Trevi Therapeutics (TRVI) Assets Average (2019 - 2026)

Trevi Therapeutics' Assets Average history runs 8 years deep, the most recent figure standing at $186.5 million for Q1 2026.

• On a quarterly basis, Assets Average rose 71.2% year-over-year to $186.5 million in Q1 2026; TTM through Mar 2026 was $186.5 million, a 71.2% increase from a year earlier, with the FY2025 full-year figure at $152.2 million, up 51.94% from the prior year.
• Assets Average declined to $186.5 million in Q1 2026 per TRVI's latest filing, from $196.4 million in the prior quarter.
• Across five years, Assets Average topped out at $203.8 million in Q3 2025 and bottomed at $34.4 million in Q1 2022.
• The 5-year median for Assets Average is $104.9 million (2022), against an average of $112.6 million.
• Across the five-year window, Assets Average soared 258.74% in 2022 and fell 29.84% in 2024, its largest moves.
• Year by year, Assets Average stood at $125.7 million in 2022, then dropped by 26.29% to $92.6 million in 2023, then decreased by 2.96% to $89.9 million in 2024, then jumped by 118.45% to $196.4 million in 2025, then dropped by 5.03% to $186.5 million in 2026.
• Per Business Quant, the three latest TRVI Assets Average figures stand at $186.5 million (Q1 2026), $196.4 million (Q4 2025), and $203.8 million (Q3 2025).